<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364556">
  <stage>Registered</stage>
  <submitdate>8/07/2013</submitdate>
  <approvaldate>11/07/2013</approvaldate>
  <actrnumber>ACTRN12613000775718</actrnumber>
  <trial_identification>
    <studytitle>The effect of enoxaparin-containing irrigation fluid during cataract surgery on post-operative inflammation in patients with diabetes</studytitle>
    <scientifictitle>The effect of enoxaparin-containing irrigation fluid during cataract surgery on post-operative inflammation in patients with diabetes; a randomized controlled clinical trial</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>post-operative inflammation after cataract surgery in patients with diabetes </healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1; Drug: Enoxaparin. It is administered during the cataract surgery. The mode of the administration is intraocular infusion. 

Enoxaparin 40 mg/500 ml in Balanced Salt Solution
Other name: clexane (Aventis)

</interventions>
    <comparator>Arm 2;  Balanced Salt Solution is used for the intraocular infusion during the cataract surgery.

Balanced Salt Solution is an isotonic solution for use in irrigating tissues of the eye.

Balanced Salt Solution is a sterile solution, each mL containing sodium chloride (NaCl) 0.64%, potassium chloride (KCl) 0.075%, calcium chloride dihydrate (CaCl2路2H2O) 0.048%, magnesium chloride hexahydrate (MgCl2路6H2O) 0.03%, sodium acetate trihydrate (C2H3NaO2路3H2O) 0.39%, sodium citrate dihydrate (C6H5Na3O7路2H2O) 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH), and water for injection.

Intraocular infusion of  Balanced Salt Solution
Other name:BSS
</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Anterior segment inflammation. 
This is assessed by slit-lamp biomicroscopy.</outcome>
      <timepoint>Time frame: 1week</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Anterior segment inflammation
This is assessed by slit-lamp biomicroscopy.</outcome>
      <timepoint>Time frame: 1month, 2 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>The study included non-insulin-dependent diabetes mellitus (NIDDM) patients that had moderate non-proliferative diabetic retinopathy (NPDR) according to Early Treatment Diabetic Retinopathy Study (ETDRS) and had grade 2-3 nuclear cataracts based on the classification of Lens Opacity Classification System III (LOCS III)</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients who underwent laser photocoagulation in the previous three months and patients with small pupils, posterior synechia and history of uveitis were excluded from the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Simple randomisation; coin-tossing</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>In the absence of available literature, we used data from a pilot study of 10 patients (10 eyes in each group) to arrive the sample size. The main outcome measure was the presence of grade 2 anterior chamber cells in the first week after the surgery.  In the first week, cells with grade 2 were seen 10% of the eyes in group1 (enoxaparin group), 50% of the eyes in group 2 (no enoxaparin group). To detect the difference of 35% between two groups, using the test of proportions at 5% level of significance, a sample size of 30 in each group was necessary to achieve 80% power

Mann-Whitney U test and the chi-square test are used to investigate differences in terms of gender and age. Fisher's exact test, chi-square test and Mann-Whitney U test are used to compare post-operative inflammation between groups. </statisticalmethods>
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/08/2010</anticipatedstartdate>
    <actualstartdate>11/08/2010</actualstartdate>
    <anticipatedenddate>28/09/2012</anticipatedenddate>
    <actualenddate>23/08/2012</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Hatay</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Ozgur Ilhan</primarysponsorname>
    <primarysponsoraddress>Mustafa Kemal University, Faculty of Medicine, Tayfur  Ata Sokmen Campus, 31120, Serinyol, Antakya, Hatay</primarysponsoraddress>
    <primarysponsorcountry>Turkey</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>None</fundingname>
      <fundingaddress>None</fundingaddress>
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress>None</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine if intraocular infusion of low-molecular weight (enoxaparin) influences post-operative inflammation following cataract surgery in patients with diabetes </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Ethics Committee of the Medical Faculty of the Mustafa Kemal University</ethicname>
      <ethicaddress>Mustafa Kemal University, Faculty of Medicine, Tayfur Ata Sokmen Campus, 31120 Serinyol, Antakya, Hatay</ethicaddress>
      <ethicapprovaldate>11/06/2010</ethicapprovaldate>
      <hrec>None</hrec>
      <ethicsubmitdate>21/05/2010</ethicsubmitdate>
      <ethiccountry>Turkey</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Ozgur Ilhan</name>
      <address>Mustafa Kemal University, Faculty of Medicine, Department of Ophthalmology, Tayfur Ata Sokmen Campus, 31120 Serinyol, Antakya, Hatay</address>
      <phone>+90 326 2291000 </phone>
      <fax />
      <email>drozgur9@mku.edu.tr</email>
      <country>Turkey</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ozgur Ilhan</name>
      <address>Mustafa Kemal University, Faculty of Medicine, Department of Ophthalmology, Tayfur Ata Sokmen Campus, 31120 Serinyol, Antakya, Hatay</address>
      <phone>+90 326 2291000 </phone>
      <fax />
      <email>drozgur9@mku.edu.tr</email>
      <country>Turkey</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ozgur Ilhan</name>
      <address>Mustafa Kemal University, Faculty of Medicine, Department of Ophthalmology, Tayfur Ata Sokmen Campus, 31120 Serinyol, Antakya, Hatay</address>
      <phone>+90 326 2291000 </phone>
      <fax />
      <email>drozgur9@mku.edu.tr</email>
      <country>Turkey</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Ozgur Ilhan</name>
      <address>Mustafa Kemal University, Faculty of Medicine, Department of Ophthalmology, Tayfur Ata Sokmen Campus, 31120 Serinyol, Antakya, Hatay</address>
      <phone>+90 326 2291000 </phone>
      <fax />
      <email>drozgur9@mku.edu.tr</email>
      <country>Turkey</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>